Sunday, 1 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Merger & Restructuring

Lupin Merger & Restructuring Worth ₹15.36 Cr

Lupin Inc. licensed two oncology programs to Kaveri Therapeutics in exchange for an 82.2% stake, valued at ₹15.36 Crore.

Key figures
Value₹15.36 Cr
Source

BSE filing, NSE: LUPIN. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Lupin Ltd: key numbers

Share price
₹2,011.00
Market cap
₹91,962 Cr
Revenue (annual)
₹27,958 Cr
Net profit (annual)
₹5,333 Cr
P/E (TTM)
16.6×Sector 45.9×
Promoter holding
46.84%-0.01% QoQ
FII holding
23.28%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Lupin Ltd

All →
20:58 IST BSE
Regulatory Approval

Lupin Regulatory Approval

Lupin Limited received U.S. FDA approval for its Abbreviated New Drug Application (ANDA) for Phytonadione Injectable Emulsion, USP (1 mg/0.5 mL single-dose prefilled syringe).

Other merger & restructuring announcements

All →